通过调节mTOR介导的免疫抑制,SPACA6宿主miR-99b~125a~let-7e集群通过调节mTOR介导的免疫抑制来塑造黑色素瘤耐药性
Viviana Vallacchi1, Gianpiero Lupoli1, Eriomina Shahaj1
1Translational Immunology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
miR-99b~125a~let-7e集群通过增加免疫抑制细胞因子和激活mTOR信号来促进黑色素瘤的耐药性. 抑制这种群体可以克服对BRAF/MEK抑制剂的耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 黑色素瘤由于基因组,非基因组和免疫变化而表现出对BRAF和MEK抑制剂的耐药性.
- 对于SPACA6宿主miR-99b~125a~let-7e微RNA集群在治疗耐药性的作用尚不清楚.
研究的目的:
- 为了研究miR-99b~125a~let-7e集群在黑色素瘤对BRAF/MEK抑制剂耐药性的功能.
- 探索集群对炎症过程和瘤微环境的影响.
主要方法:
- 在黑色素瘤患者的瘤和细胞系中分析miRNA表达的分析,治疗反应和耐药性各不相同.
- 在黑色素瘤细胞中的miR-99b~125a~let-7e集群的抑制和过度表达研究.
- 在基因目标基因分析和RNA测序 (RNA-seq) 与患者衍生的黑色素瘤扩散物的蛋白质特征分析.
主要成果:
- miR-99b,miR-125a和let-7e在进展性瘤和抗性黑色素瘤细胞系中被上调,与免疫抑制性细胞因子增加相关.
- 集群的联合抑制降低了耐药细胞的增殖和促炎性细胞因子表达 (CCL2,IL6,IL8).
- 目标基因分析确定了GNAI1,ADCY1和NR6A1参与脂质代谢和mTOR信号传递,在耐药细胞中下调调节. 集群的抑制重新编程了瘤微环境,增强了免疫激活和抑制mTOR信号.
结论:
- 托管SPACA6的miR-99b~125a~let-7e集群通过促进瘤存活和免疫抑制微环境,促进BRAF/MEK抑制剂耐药性.
- 针对这种miRNA集群是一个潜在的治疗策略,以克服转移性黑色素瘤中耐药性的治疗.
相关概念视频
07:41A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
06:01Modulating Shape of Polyester Based Polymersomes using Osmotic Pressure
08:17VIGS-Mediated Forward Genetics Screening for Identification of Genes Involved in Nonhost Resistance
Virus-induced gene silencing is an useful tool for identifying genes involved in nonhost resistance of plants. We demonstrate the use of bacterial pathogens expressing GFPuv in identifying gene silenced plants susceptible to nonhost pathogens. This approach is easy, fast and facilitates large scale screening and similar protocol can be applied to studying various other plant-microbe...
08:39Shaping the Amplitude and Phase of Laser Beams by Using a Phase-only Spatial Light Modulator
10:40CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy


